These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34062472)

  • 21. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
    Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Park JS; Park HY; Choi Y
    Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
    Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
    Shi YM; Niu R; Shao XL; Zhang FF; Shao XN; Wang JF; Wang XS; Liu B; Yu WJ; Wang YT
    Nucl Med Commun; 2020 May; 41(5):459-468. PubMed ID: 32187163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review and meta-analysis of
    Reinders Folmer EI; von Meijenfeldt GCI; Te Riet Ook Genaamd Scholten RS; van der Laan MJ; Glaudemans AWJM; Slart RHJA; Zeebregts CJ; Saleem BR
    J Vasc Surg; 2020 Dec; 72(6):2174-2185.e2. PubMed ID: 32645420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic ability of
    Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
    Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the correlation between HER2 alterations and
    Ruan M; Chang C; Sun J; Liu L; Wang L; Lei B; Yan H; Zhang H; Xie W; Wang Y
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14493-14507. PubMed ID: 37572120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
    Meng N; Fu F; Feng P; Li Z; Gao H; Wu Y; Zhang J; Wei W; Yuan J; Yang Y; Liu H; Cheng J; Wang M
    J Magn Reson Imaging; 2022 Oct; 56(4):1118-1129. PubMed ID: 35258145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of pre-therapy
    Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Accuracy of F18-fluorodeoxyglucose Positron Emission Tomography- computed Tomography for the Detection of Non-small Cell Lung Cancer Recurrence: A Systematic Review and Meta-analysis.
    Chen Y; Zhang D; Fan K
    Curr Med Imaging; 2022; 19(5):476-485. PubMed ID: 35927894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.
    Simsek FS; Arslan M; Dag Y
    Bosn J Basic Med Sci; 2019 May; 19(2):195-200. PubMed ID: 30997878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on
    Koyasu S; Nishio M; Isoda H; Nakamoto Y; Togashi K
    Ann Nucl Med; 2020 Jan; 34(1):49-57. PubMed ID: 31659591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A; Yazici B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.